This July, Mayo Clinic’s Neuroimmunology Laboratory will showcase its revolutionary approach to autoimmune neurology testing at the American Academy of Neurology (AAN) Summer Conference: Autoimmune Neurology and Neurology Year in Review in San Francisco. During the meeting, Mayo Clinic Laboratories representatives will highlight our growing list of disease-specific tests and discuss how results can inform decision-making and improve treatment outcomes.
PACE/State of CA/State of FL - In this month’s “Virtual Lecture,” John Mills, Ph.D., provides information related to work that has been done in Mayo Clinic’s neuroimmunology laboratory which has played a central role in driving the field of autoimmune neurology. Over time it has driven an increase in testing volume, a number of different testing platforms, testing complexity, and a constant influx of novel laboratory-developed tests.
Join Mayo Clinic’s autoimmune neurology testing leaders for a live Zoom Q&A discussion as they discuss the rationale behind and benefits of Mayo Clinic Laboratories’ streamlined, phenotype-specific approach to testing for autoimmune neurological disorders.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Mayo Clinic Laboratories is leading an evolution in autoimmune neurology diagnosis. To better reflect this testing evolution, and to reduce confusion and improve utilization for our clients, effective April 28, we are renaming our phenotype-specific evaluations.
Andrew McKeon, M.B., B.Ch., M.D., an expert in neuroimmunology, joins the "Answers From the Lab" podcast for a conversation with Bobbi Pritt, M.D. In this episode, Dr. McKeon and Dr. Pritt discuss how Mayo Clinic is pioneering advancements in the field of autoimmune neurology, how these discoveries were made, and why they are important to both patients and physicians.
PACE/State of CA/State of FL - Presentation Recording Coming Soon -
This “Specialty Testing” webinar will discuss the considerations physicians must weigh when evaluating suspected neuropathy patients with special emphasis put on small-fiber neuropathy and the most appropriate laboratory testing related to that phenotype.
Sophisticated laboratory testing solved a medical riddle and finally got Jori Pearson back on his feet, doing what he loves.
Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay can help confirm the most-severe stiff-person phenotype — known as PERM — which is associated with potential cancers.
Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.